(Q53332226)

13 May 2018

title

Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease. (English)

1 reference

13 May 2018

3

Jeffrey L Cummings

1 reference

13 May 2018

Stephen Salloway

1

1 reference

13 May 2018

Jacobo Mintzer

2

1 reference

13 May 2018

David Geldmacher

4

1 reference

13 May 2018

Yijun Sun

5

1 reference

13 May 2018

Jane Yardley

6

1 reference

13 May 2018

Joan Mackell

7

1 reference

13 May 2018

language of work or name

English

0 references

publication date

1 September 2012

1 reference

13 May 2018

American Journal of Alzheimer's Disease & Other Dementias

published in

1 reference

13 May 2018

volume

27

1 reference

13 May 2018

issue

6

1 reference

13 May 2018

page(s)

421-432

1 reference

13 May 2018

Donepezil preserves cognition and global function in patients with severe Alzheimer disease

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

Education and rates of cognitive decline in incident Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

Rate of memory decline in AD is related to education and occupation: cognitive reserve?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

Influence of apolipoprotein E ɛ4 on rates of cognitive and functional decline in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

Vitamin E and donepezil for the treatment of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

Efficacy and safety of donepezil in patients with Alzheimer's disease in assisted living facilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

Safety and tolerability of donepezil in mild cognitive impairment: open-label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317512454708

21 January 2018

Identifiers

DOI

10.1177/1533317512454708

1 reference

13 May 2018

1 reference

13 May 2018